Stealth BioTherapeutics Corp. announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's financial team.
Stealth BioTherapeutics Corp
Equities
MITO
US85789A1051
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |